Vanguard Global Advisers
BEAM icon

Vanguard Global Advisers’s Beam Therapeutics BEAM Stock Holding History

Vanguard Global Advisers’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
38,064
-1,348
-3% -$40.7K ﹤0.01% 1574
2026
Q1 		$939K Buy
+39,412
New +$1.09M ﹤0.01% 1683

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Global Advisers's BEAM Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Beam Therapeutics (BEAM) stake by 3.4% in Q2 2026, selling an estimated $40.7K and leaving 38,064 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Vanguard Global Advisers first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 274 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vanguard Global Advisers held 38,064 shares of Beam Therapeutics worth $1.31M as of Q2 2026.
  • Vanguard Global Advisers sold 1,348 Beam Therapeutics shares in Q2 2026, an estimated $40.7K.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1574 holding.
  • Vanguard Global Advisers first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 274 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.